- Conditions
- Parkinson Disease, Depression
- Interventions
- Psilocybin, Pimavanserin
- Drug
- Lead sponsor
- Joshua Woolley, MD, PhD
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–37
of 37
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neuropsychiatric Symptoms Related to Neurodegenerative Disease
- Interventions
- Pimavanserin, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 21
- States / cities
- Gilbert, Arizona • Costa Mesa, California • Santa Ana, California + 13 more
- Conditions
- Adjunctive Treatment of Major Depressive Disorder
- Interventions
- Pimavanserin, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Garden Grove, California • Glendale, California + 34 more
- Conditions
- Agitation and Aggression in Alzheimer's Disease
- Interventions
- Pimavanserin 34 mg, Pimavanserin 20 mg, Placebo
- Drug · Other
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 33
- States / cities
- Costa Mesa, California • Fresno, California • Fullerton, California + 30 more
- Conditions
- Parkinson's Disease
- Interventions
- Pimavanserin, Placebo, Quetiapine
- Drug · Other
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more
- Conditions
- Mood (Psychological Function), Well Being, Mood, Healthy
- Interventions
- Psilocybin, Pimavanserin, Inactive Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Major Depressive Disorder
- Interventions
- Psilocybin, Pimavanserin, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adjunctive Treatment of Major Depressive Disorder
- Interventions
- Pimavanserin, Placebo
- Drug · Other
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more
- Conditions
- Schizophrenia
- Interventions
- Pimavanserin, Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Rogers, Arkansas • Bellflower, California + 27 more
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- Pimavanserin tartrate (ACP-103)
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 26
- States / cities
- La Habra, California • Laguna Hills, California • Reseda, California + 22 more
- Conditions
- Post-traumatic Stress Disorder, Insomnia
- Interventions
- pimavanserin, Placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Schizophrenia
- Interventions
- Pimavanserin
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 995 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more
- Conditions
- Parkinson's Disease Psychosis, Dementia With Lewy Bodies
- Interventions
- Pimavanserin, Quetiapine
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- Not listed
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas